| Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease AR Weingarden, BP Vaughn Gut microbes 8 (3), 238-252, 2017 | 370 | 2017 |
| Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study BP Vaughn, M Martinez-Vazquez, VR Patwardhan, AC Moss, ... Inflammatory bowel diseases 20 (11), 1996-2003, 2014 | 241 | 2014 |
| Increased intestinal microbial diversity following fecal microbiota transplant for active Crohn's disease BP Vaughn, T Vatanen, JR Allegretti, A Bai, RJ Xavier, J Korzenik, ... Inflammatory bowel diseases 22 (9), 2182-2190, 2016 | 236 | 2016 |
| Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab K Papamichael, KA Chachu, RK Vajravelu, BP Vaughn, J Ni, ... Clinical Gastroenterology and Hepatology 15 (10), 1580-1588. e3, 2017 | 226 | 2017 |
| Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection A Khoruts, KM Rank, KM Newman, K Viskocil, BP Vaughn, MJ Hamilton, ... Clinical Gastroenterology and Hepatology 14 (10), 1433-1438, 2016 | 224 | 2016 |
| Successful resolution of recurrent Clostridium difficile infection using freeze-dried, encapsulated fecal microbiota; pragmatic cohort study C Staley, MJ Hamilton, BP Vaughn, CT Graiziger, KM Newman, ... Official journal of the American College of Gastroenterology| ACG 112 (6 …, 2017 | 201 | 2017 |
| Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared with standard of care in patients with inflammatory bowel disease K Papamichael, A Juncadella, D Wong, S Rakowsky, LA Sattler, ... Journal of Crohn's and Colitis 13 (8), 976-981, 2019 | 132 | 2019 |
| Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease K Papamichael, RK Vajravelu, BP Vaughn, MT Osterman, AS Cheifetz Journal of Crohn's and Colitis 12 (7), 804-810, 2018 | 117 | 2018 |
| Purinergic signalling in the liver in health and disease G Burnstock, B Vaughn, SC Robson Purinergic signalling 10, 51-70, 2014 | 104 | 2014 |
| Clostridium difficile Infection and Fecal Microbiota Transplant A Liubakka, BP Vaughn AACN advanced critical care 27 (3), 324-337, 2016 | 89 | 2016 |
| Biologic concentration testing in inflammatory bowel disease BP Vaughn, WJ Sandborn, AS Cheifetz Inflammatory bowel diseases 21 (6), 1435-1442, 2015 | 87 | 2015 |
| Bilirubin suppresses Th17 immunity in colitis by upregulating CD39 MS Longhi, M Vuerich, A Kalbasi, JE Kenison, A Yeste, E Csizmadia, ... JCI insight 2 (9), 2017 | 83 | 2017 |
| Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised … L Peyrin-Biroulet, A Hart, P Bossuyt, M Long, M Allez, P Juillerat, ... The lancet Gastroenterology & hepatology 7 (2), 128-140, 2022 | 82 | 2022 |
| Predicting recurrence of Clostridium difficile infection following encapsulated fecal microbiota transplantation C Staley, T Kaiser, BP Vaughn, CT Graiziger, MJ Hamilton, T Rehman, ... Microbiome 6, 1-13, 2018 | 81 | 2018 |
| High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines KA Pape, T Dileepan, AJ Kabage, D Kozysa, R Batres, C Evert, M Matson, ... Cell Reports 37 (2), 2021 | 78 | 2021 |
| A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis BP Vaughn, T Kaiser, C Staley, MJ Hamilton, J Reich, C Graiziger, ... Clinical and experimental gastroenterology, 9-19, 2019 | 76 | 2019 |
| Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease KM Newman, KM Rank, BP Vaughn, A Khoruts Gut microbes 8 (3), 303-309, 2017 | 76 | 2017 |
| Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials DT Rubin, I Dotan, A DuVall, Y Bouhnik, G Radford-Smith, PDR Higgins, ... The lancet Gastroenterology & hepatology 7 (1), 17-27, 2022 | 74 | 2022 |
| Maintenance adalimumab concentrations are associated with biochemical, endoscopic, and histologic remission in inflammatory bowel disease A Juncadella, K Papamichael, BP Vaughn, AS Cheifetz Digestive diseases and sciences 63, 3067-3073, 2018 | 73 | 2018 |
| Pathological roles of purinergic signaling in the liver BP Vaughn, SC Robson, G Burnstock Journal of hepatology 57 (4), 916-920, 2012 | 73 | 2012 |
Alexander KhorutsProfessor of Medicine, University of Minnesota在 umn.edu 的电子邮件经过验证
